Drug Trial Radar · NCT07669519
Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Natureceuticals Sdn BhdIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: Does Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population? Researchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile. Participants will: Receive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days). Continue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment. Complete patient diaries and fatigue assessments as per protocol.
Conditions
- Fatigue
- Colon Cancer
Interventions
Nuvastatic™Drug
1000mg Sachet, (1 sachet X 3 times a day)
PlaceboDrug
1000mg sachet, (1 sachet X 3 times a day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.Time frame: from screening up to 12 weeks
- Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.Time frame: From Screening up to 12 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Department of Medical Oncology (In Charge - Oncology Unit)
Srikakulam, Andhra Pradesh, India · Recruiting
Hanji Cancer Centre
Belagavi, Karnataka, India · Recruiting
K.R. Hospital, Mysore Medical College & Research Institute
Mysuru, Karnataka, India · Recruiting
Onco- Life Cancer
Satara, Maharashtra, India · Recruiting
Onco-Life Cancer Centre, Pvt. Ltd
Talegaon Dābhāde, Maharashtra, India · Recruiting
Avicenna Hospital
Lucknow, Uttar Pradesh, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.